CJC-1295 No DAC Dosing Guide: Mod GRF, Timing & Safety (2026)

CJC-1295 No DAC, also called Modified GRF 1-29 or Mod GRF 1-29, is a short-acting copy of the body's own growth-hormone-releasing hormone (GHRH). It tells the pituitary gland to release a short burst of growth hormone, then clears the body in about 30 minutes.

Researchers planning protocols usually pair it with Ipamorelin because the two compounds push the pituitary through different doors at the same time. CJC-1295 No DAC is not FDA-approved and is used only in research-reference contexts.

This no-DAC page covers dose timing and setup. Want the bigger CJC view? See the CJC-1295 research overview. It covers effects, studies, safety notes, and legal status.

Most CJC-1295 No DAC research protocols start low and increase slowly. The short half-life means each dose is mostly independent, so timing the dose around fasted windows usually matters more than chasing a higher number.

Researchers describe a saturation point: roughly 100 mcg seems to fill the available pituitary receptors for a single pulse. Pushing past that with a larger single dose does not usually create a much larger growth hormone burst. That is why most planning frameworks add a second daily injection before they raise the size of one dose.

The default setup on this page is the 10 mg vial with 3 mL bacteriostatic water. That gives a working solution of about 3,333 mcg/mL, which makes the most common research doses snap to clean unit numbers on a U-100 insulin syringe.

This CJC-1295 No DAC dosage chart summarizes a common daily titration schedule from 100 mcg up to 200 mcg, with optional advanced dosing shown by week range.

CJC-1295 No DAC is a small change to the body's own growth-hormone-releasing hormone (GHRH). Four edits to the sequence make it last longer than natural GHRH, which only survives a few minutes. The change gives it a half-life of about 30 minutes.

Once injected, CJC-1295 No DAC travels to the pituitary gland — a small structure at the base of the brain that controls many hormones. It attaches to GHRH receptors on the pituitary and tells the gland to release growth hormone (GH).

Because the compound clears in about 30 minutes, each dose makes one short GH burst, then fades. That pulsatile pattern is closer to how the body normally releases GH in waves, especially during deep sleep. Many planning frameworks favor it over long-acting compounds because the pulse-and-rest pattern may help keep receptors responsive over time.

Each GH pulse signals the liver to produce IGF-1 (insulin-like growth factor 1). IGF-1 is one of the markers researchers track because it carries many of the downstream effects on tissue, muscle, and metabolism.

Ipamorelin is a different kind of GH stimulator. It works through the ghrelin receptor, not the GHRH receptor. Pushing both doors at once usually creates a larger GH pulse than either compound alone. That is why CJC-1295 No DAC + Ipamorelin is one of the most discussed GH-related stack patterns in research planning.

This page is a research-planning reference. The note below covers who research protocols typically exclude, not who can or cannot use the compound personally. There is no human-use approval, and the decision should always involve a licensed clinician.

CJC-1295 No DAC is often described as easier to titrate than the DAC version because side effects fade with the compound itself. Most reported effects pass within 30–60 minutes of a dose.

Higher single doses tend to produce more flushing and headache without a proportional GH gain. This is part of why most planning frameworks add a second daily dose before they raise the size of a single dose.

A 2006 Phase 2 trial of CJC-1295 with DAC in HIV patients was halted after a participant had a heart attack. Investigators later said the event was unrelated to the compound, but the program was discontinued. That event is tied to the DAC version, which keeps GH levels elevated for days. No similar signal has been reported for the No DAC variant.

Because CJC-1295 No DAC is sold as a research compound, purity and identity vary by supplier. Match the certificate of analysis (COA) to the exact product and batch where possible. PepPal tracks COA depth and independent testing on its supplier comparison pages.

There is no large outcome trial that maps response timelines for the No DAC variant. The general timing markers below come from parent-compound research, GH/IGF-1 physiology, and community planning.

Human evidence for the No DAC variant specifically is limited. Most published human data covers the parent CJC-1295 sequence, with several Phase 1 studies and one halted Phase 2 trial.

No large clinical trial has been run specifically on the No DAC variant. Current dosing patterns rest on the parent CJC-1295 research above, the physiology of GHRH signaling, and the simple fact that the No DAC version uses the same receptor with a much shorter half-life. The cardiac event in the Phase 2 trial is tied to the DAC variant, not the short-acting No DAC version.

Discard the vial. Reconstituted CJC-1295 No DAC should be clear and colorless. Cloudiness usually means contamination or peptide degradation.

The peptide is not ruined if your concentration is different from the chart. Recalculate the unit count using your real volume. Add the new concentration label to the vial so you do not draw the old dose by mistake. The calculator can handle any vial / volume combo.

Skip it and resume the schedule. The half-life is short, so each dose is largely independent. Do not double up the next day.

Usually a sign the per-dose number is too high. Most planning frameworks step back to 100 mcg and add frequency before going higher. Effects usually fade within 30–60 minutes.

Short shipping windows are normal. Long room-temperature exposure after reconstitution shortens stability. If reconstituted product has been warm for more than a day or two, treat it as suspect.

Most plans start once daily pre-bed, then add a morning fasted dose only after the single dose is tolerated. Twice daily is not required.

As of May 2026, CJC-1295 No DAC (Modified GRF 1-29) is not FDA-approved. It has no active clinical development pathway tied to the No DAC variant. It sits in the same category as many other research-use peptides and is sold for research reference, not human use.

Regulatory status changes from time to time. Confirm current FDA status on the FDA website before relying on any planning document.

CJC-1295 No DAC sits in a family of GH-related research compounds. The table below lines up the four most often compared.

Compound-specific guides: CJC-1295 with DAC, Sermorelin, and Ipamorelin.

CJC-1295 without DAC is usually discussed as a shorter GH-pulse support peptide. Monitoring focuses on IGF-1 trends, glucose handling, lipids, and fluid-retention symptoms.